{"changes":[],"country":"US","description":"Terremoto Biosciences develops oral small-molecule drugs using novel covalent chemistry for surgical selectivity against AKT1 in cancer and hereditary hemorrhagic telangiectasia. Its covalency platform unlocks previously undruggable targets, serving patients where earlier AKT inhibitors failed on safety or durability grounds.","domain":"terremoto.bio","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco, USA","name":"Terremoto Biosciences","rounds":[{"amountQuarantined":false,"amountUsd":108000000,"currency":"USD","date":"2026-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-04-29","status":"attributed","url":null},"status":"attributed","type":"series-d+","url":null}],"slug":"terremoto-bio","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-04-29","status":"attributed","url":null},{"fact":"existence","publisher":"terremoto.bio","retrievedAt":"2026-04-29","status":"self-reported","url":"https://terremoto.bio"},{"fact":"description","publisher":"terremoto.bio","retrievedAt":"2026-04-29","status":"self-reported","url":"https://terremoto.bio"}],"stage":"series-b+","techStack":["Cloudflare","All in One SEO 4.9.7.2","All in One SEO Pack 4.9.7.2","Kinsta","Google Analytics","Google Tag Manager","Slick 1.8.1","jQuery Migrate 3.4.1","parallax.js","DoubleClick Floodlight","cdnjs","Cloudflare Bot Management"],"totalRaisedUsd":250000000,"updatedAt":"2026-04-29"}